Table 1. Characteristics of patients and... | American Society of Hematology

Table 1.

Characteristics of patients and healthy individuals

Characteristics	Patients with ET	Patients with ST	Healthy individuals
No.	75	27	20
Age
Mean, y	50	48.8	40
Median, y	47	54	39
Range, y	24-83	2-80	22-51
Sex, no. male/no. female	24/51	17/10	13/7
Hemoglobin level
Mean, g/dL	13.4	11	13.7
Median, g/dL	13.5	10.5	13.7
Range, g/dL	7.6-16.2	7.4-22	12-15.6
Hematocrit level (%)
Mean	41.4	33.5	42
Median	41.6	31.6	42
Range	24.5-50.7	22-43	37-47
No. leukocytes
Mean, ×10⁹/L	8.9	11.9	6.6
Median, ×10⁹/L	8.4	10.6	6.7
Range, ×10⁹/L	4.8-24.5	6-32.4	4-9.8
No. platelets
Mean, ×10⁹/L	808	717	239
Median, ×10⁹/L	721	656	223
Range, ×10⁹/L	419-3500	605-1500	152-447
No. subjects with splenomegaly Treatment	27	0	0
None, no. subjects	54	27	0
HU, no. subjects	13	0	0
IFN, no. subjects	6	0	0
Anagrelide, no. subjects	2	0	0

Characteristics	Patients with ET	Patients with ST	Healthy individuals
No.	75	27	20
Age
Mean, y	50	48.8	40
Median, y	47	54	39
Range, y	24-83	2-80	22-51
Sex, no. male/no. female	24/51	17/10	13/7
Hemoglobin level
Mean, g/dL	13.4	11	13.7
Median, g/dL	13.5	10.5	13.7
Range, g/dL	7.6-16.2	7.4-22	12-15.6
Hematocrit level (%)
Mean	41.4	33.5	42
Median	41.6	31.6	42
Range	24.5-50.7	22-43	37-47
No. leukocytes
Mean, ×10⁹/L	8.9	11.9	6.6
Median, ×10⁹/L	8.4	10.6	6.7
Range, ×10⁹/L	4.8-24.5	6-32.4	4-9.8
No. platelets
Mean, ×10⁹/L	808	717	239
Median, ×10⁹/L	721	656	223
Range, ×10⁹/L	419-3500	605-1500	152-447
No. subjects with splenomegaly Treatment	27	0	0
None, no. subjects	54	27	0
HU, no. subjects	13	0	0
IFN, no. subjects	6	0	0
Anagrelide, no. subjects	2	0	0

ET denotes essential thrombocythemia; ST, secondary thrombocytosis; HU, hydroxyurea; and IFN, interferon.